The role of epigenetics in the biology of multiple myeloma
Open Access
- 2 May 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 4 (5), e207
- https://doi.org/10.1038/bcj.2014.29
Abstract
Several recent studies have highlighted the biological complexity of multiple myeloma (MM) that arises as a result of several disrupted cancer pathways. Apart from the central role of genetic abnormalities, epigenetic aberrations have also been shown to be important players in the development of MM, and a lot of research during the past decades has focused on the ways DNA methylation, histone modifications and noncoding RNAs contribute to the pathobiology of MM. This has led to, apart from better understanding of the disease biology, the development of epigenetic drugs, such as histone deacetylase inhibitors that are already used in clinical trials in MM with promising results. This review will present the role of epigenetic abnormalities in MM and how these can affect specific pathways, and focus on the potential of novel ‘epidrugs’ as future treatment modalities for MM.Keywords
This publication has 101 references indexed in Scilit:
- Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancerNature Reviews Genetics, 2013
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood, 2013
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-EnhancersCell, 2013
- The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myelomaBlood Cancer Journal, 2012
- Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF-κB Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward LoopMolecular and Cellular Biology, 2012
- Multiple MyelomaThe New England Journal of Medicine, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- The effect of azacitidine on interleukin-6 signaling and nuclear factor- B activation and its in vitro and in vivo activity against multiple myelomaHaematologica, 2008
- Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survivalBritish Journal of Haematology, 2002